Acutaas Chemicals Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Acutaas Chemicals Ltd filed with BSE on 28 Jul 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Acutaas Chemicals reported Q1 FY27 revenue of INR329.7 crores, up 59.1% year-on-year, with EBITDA margin expanding to 34.3% and PAT of INR74.9 crores. Management attributed the growth to strong performance in the Advanced Pharmaceutical Intermediates segment, particularly CDMO, while the Specialty Chemicals segment declined due to the planned phase-out of commodity chemicals. The company also reported completion of trial runs at its new battery chemicals plant and commencement of commercial supply, along with progress on the Indichem semiconductor chemicals plant in Korea.
Numbers mentioned
Revenue: INR329.7 crores (Q1 FY27)
p. 4
“We delivered strong revenue of INR329.7 crores, which is growth of 59.1% Y-o-Y.”
Naresh Patel, page 4 of the filed PDF · View the filing
Advanced Pharmaceutical Intermediates segment revenue: INR292.7 crores (Q1 FY27)
p. 4
“this segment delivered robust performance with revenue of INR292.7 crores in Q1 FY '27, reflecting a strong year-on-year growth of 76.5%”
Abhishek Patel, page 4 of the filed PDF · View the filing
Specialty Chemicals segment revenue: INR37 crores (Q1 FY27)
p. 4
“Revenue stood at INR37 crores for this quarter in this segment, a decline of 10.6% Y-on-Y.”
Abhishek Patel, page 4 of the filed PDF · View the filing
Capex: INR56 crores (Q1 FY27)
p. 5
“capex for Q1 FY '27 stood at INR56 crores, out of which INR15 crores were at the Indichem site, remaining INR41 crores in ACL site”
Abhishek Patel, page 5 of the filed PDF · View the filing
Gross profit: INR190.9 crores (Q1 FY27)
p. 5
“Gross profit for the quarter was INR190.9 crores, reflecting a 73% increase compared to the same period last year.”
Bhavin Shah, page 5 of the filed PDF · View the filing
Gross margin: 57.9% (Q1 FY27)
p. 5
“The gross margin expanded by 466 basis points Y-o-Y to 57.9%.”
Bhavin Shah, page 5 of the filed PDF · View the filing
EBITDA: INR113.1 crores (Q1 FY27)
p. 5
“EBITDA for the quarter was INR113.1 crores, which represents more than twofold increase compared to the EBITDA of the same period last year.”
Bhavin Shah, page 5 of the filed PDF · View the filing
EBITDA margin: 34.3% (Q1 FY27)
p. 5
“EBITDA margin were at 34.3%, up 973 basis points Y-o-Y.”
Bhavin Shah, page 5 of the filed PDF · View the filing
PAT: INR74.9 crores (Q1 FY27)
p. 5
“PAT for the quarter was INR74.9 crores, up 70.4% Y-o-Y.”
Bhavin Shah, page 5 of the filed PDF · View the filing
PAT margin: 22.7% (Q1 FY27)
p. 5
“PAT margins for the quarter were at 22.7%, which show an expansion of 151 basis points Y-o-Y.”
Bhavin Shah, page 5 of the filed PDF · View the filing
Net cash and cash equivalents: INR314 crores (as on 30th June 2026)
p. 5
“Net cash and cash equivalents were around INR314 crores as on 30th June 2026.”
Bhavin Shah, page 5 of the filed PDF · View the filing
Working capital days: 99 days (Q1 FY27)
p. 5
“Our working capital for the quarter stands at 99 days versus 91 days in Q4 FY '26.”
Bhavin Shah, page 5 of the filed PDF · View the filing
Specialty Chemicals margin: 24%
p. 6
“our Spec Chem business is having around 24% margin and Pharma business is having around 36% margin”
Bhavin Shah, page 6 of the filed PDF · View the filing
Capacity utilization - Sachin unit: 83% (Q1 FY27)
p. 13
“For the capacity utilization for the Sachin unit, the capacity is 83%.”
Abhishek Patel, page 13 of the filed PDF · View the filing
Capacity utilization - Ankleshwar Unit 2: 23% (Q1 FY27)
p. 13
“For Unit 2 at Ankleshwar, it is 23% and at Unit 3 Jhagadia, 55% for the quarter.”
Abhishek Patel, page 13 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — 25% · FY27
stated firmly by Naresh Patel
p. 4
“I remain confident of delivering 25% revenue growth for the full year with stable margins.”
Naresh Patel, page 4 of the filed PDF · View the filing
EBITDA margin — similar to FY26 · FY27
stated firmly by Abhishek Patel
p. 8
“For current financial year, for the full year, as we guided during the commentary also, we are expecting a similar kind of margin as we had for full year FY '26.”
Abhishek Patel, page 8 of the filed PDF · View the filing
Employee cost — INR150 crores · current year
stated firmly by Bhavin Shah
p. 7
“We should typically look at around INR150 crores of employee cost for the current year.”
Bhavin Shah, page 7 of the filed PDF · View the filing
Electrolyte Additives Phase 2 capex completion — end of Q2 FY27
stated firmly by Abhishek Patel
p. 7
“as we mentioned earlier also by end of Q2 FY '27, we would be completing our capex.”
Abhishek Patel, page 7 of the filed PDF · View the filing
Indichem plant capex completion — end of this quarter
stated firmly by Abhishek Patel
p. 6
“this is getting constructed even before the schedules and expected to get -- capex is expected to get completed by end of this quarter.”
Abhishek Patel, page 6 of the filed PDF · View the filing
Indichem revenue — next financial year onwards
stated firmly by Abhishek Patel
p. 6
“maybe from next financial year onwards, we will have the revenue coming up from that plant.”
Abhishek Patel, page 6 of the filed PDF · View the filing
Battery chemicals plant capacity utilization — full capacity · 3 years
stated firmly by Abhishek Patel
p. 14
“we are more than confident that we will be able to hit the full capacity utilization by end of 3 years.”
Abhishek Patel, page 14 of the filed PDF · View the filing
CDMO revenue — INR1,000 crores
stated firmly by Abhishek Patel
p. 10
“we have already guided the market that we would be hitting INR1,000 crores revenue from our CDMO business.”
Abhishek Patel, page 10 of the filed PDF · View the filing
CDMO validated products revenue — INR50 crores to INR100 crores each per year at peak · H2 FY27 onwards
stated firmly by Abhishek Patel
p. 13
“we are expecting revenue to kick in from H2 FY '27 onwards. And on a revenue potential side, these all products are expected to generate revenue between INR50 crores to INR100 crores for each year at a peak.”
Abhishek Patel, page 13 of the filed PDF · View the filing
Pharma Intermediates revenue share of total revenue — around 80% from 87% · next 3 years
stated as an aspiration by Abhishek Patel
p. 15
“we can expect that this revenue composition should come down to around maybe 80% from 87% in next 3 years' time.”
Abhishek Patel, page 15 of the filed PDF · View the filing
Ankleshwar plant capacity — 3 years, maybe by FY28
stated conditionally by Abhishek Patel
p. 8
“the Ankleshwar plant is expected to get filled up in 3 years' time, maybe by FY '28.”
Abhishek Patel, page 8 of the filed PDF · View the filing
Indichem full capacity utilization — full capacity · 3 to 4 years
stated as an aspiration by Abhishek Patel
p. 12
“It will be a slow start because it's a new business, but maybe in 3 to 4 years' time, we should be able to fill up our full capacity at Indichem.”
Abhishek Patel, page 12 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management confirmed supply has started from the new plant but declined to give a specific number, expressing confidence in fast growth given existing supply contracts.
Answered by Abhishek Patel
Asked by Abhijit Akella: Are there battery chemicals revenues recognized this quarter and what revenue can be expected for the rest of the year?
p. 6
“I'm afraid I will not be able to share the a particular number to it, but we are very confident that we will grow very fast in those 2 business because, as you know, we have already supply contract in place from our customer, and it will ramp up very fast going forward.”
Abhishek Patel, page 6 of the filed PDF · View the filing
Management guided to around INR150 crores of employee cost for the current year, citing annual increments and one-time performance bonuses.
Answered by Bhavin Shah
Asked by Nilesh Ghuge: What employee cost figure should be used going forward?
p. 7
“We should typically look at around INR150 crores of employee cost for the current year.”
Bhavin Shah, page 7 of the filed PDF · View the filing
Management explained the decline was due to a large positive exchange fluctuation on the euro in the prior quarter that did not repeat.
Answered by Bhavin Shah
Asked by Abhigyan Srivastav: Why did other income decline sharply this quarter?
p. 9
“in previous quarter, it was largely driven by positive exchange fluctuation rate available with regard to euro. So in current quarter, we have only positive fluctuation of INR10 lakhs as compared to INR10 crores in the previous quarter.”
Bhavin Shah, page 9 of the filed PDF · View the filing
Management said the business has multiple customers across North America, Korea, and other regions.
Answered by Abhishek Patel
Asked by Rohit Nagraj: Is the battery chemicals business dependent on a single customer or multiple customers, and which geographies?
p. 11
“It's not driven by single customer. There are multiple customers. We have time to time shared that we have a number of customers already in place for both VC and FEC.”
Abhishek Patel, page 11 of the filed PDF · View the filing
Management said Pharma Intermediates revenue share, currently 87%, is expected to decline to around 80% within three years as newer businesses grow.
Answered by Abhishek Patel
Asked by Manav Kapasi: How will the revenue mix between Pharma Intermediates and Specialty Chemicals change over the next few years?
p. 15
“last financial year, our total revenue from Pharma Intermediate business were 87% of the total revenue and 13% was the Spec Chem business.”
Abhishek Patel, page 15 of the filed PDF · View the filing
Management said ongoing R&D pipeline additions will gradually dilute the revenue concentration from any single product.
Answered by Abhishek Patel
Asked by Tirumala Reddy: How is the company addressing revenue concentration risk in CDMO/Pharma Intermediates from a few molecules?
p. 16
“it will get diluted over the years once the new CDMO and other products keep on adding to the basket.”
Abhishek Patel, page 16 of the filed PDF · View the filing
Management said there is no plan to move up the value chain into APIs, citing a policy against competing with customers.
Answered by Abhishek Patel
Asked by Tirumala Reddy: Does the company plan to move forward into API manufacturing given customer inquiries?
p. 16
“we do not have any plan move to the upward in the value chain. We do not compete our customer. That's our policy, and we would like to stick to it.”
Abhishek Patel, page 16 of the filed PDF · View the filing
Risks flagged
Geopolitical tensions in the Gulf affecting raw material availability and supply continuity
p. 3
“We began the financial year on a turbulent note, driven by geopolitical tensions in the Gulf.”
Naresh Patel, page 3 of the filed PDF · View the filing
Transition gap between phasing out old commodity chemical products and ramping up new higher-margin products
p. 4
“As a result, there may be a transition gap between phasing out of the old product and ramp-up of revenue for new ones.”
Abhishek Patel, page 4 of the filed PDF · View the filing
Revenue concentration in CDMO business tied to a few molecules
p. 16
“because of the very fast ramp-up in this particular product, the revenue concentration moved towards that product”
Abhishek Patel, page 16 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.